AUS
NZ
UK
CA
USA
IND
Highlights
Advances in medical technology are transforming the diagnosis and treatment of traumatic brain injury (TBI), enhancing care options for those affected.
Companies listed on the ASX are pioneering developments in drug research and medical devices to improve TBI detection and therapeutic interventions.
Innovations such as portable brain scanners, biomarker tracking, and neuroprotective drug therapies are expanding treatment possibilities for TBI.
March is recognized as Traumatic Brain Injury (TBI) Awareness Month, bringing attention to the challenges faced by individuals living with brain injuries. TBI occurs when a significant impact to the head disrupts normal brain function. The severity can range from mild concussions to more serious injuries that impair cognitive and motor abilities or lead to life-threatening conditions.
Different types of TBIs include hematomas, skull fractures, and contusions, often caused by internal bleeding or swelling. The long-term effects of repeated head trauma can result in conditions such as chronic traumatic encephalopathy (CTE) and post-traumatic dementia (PTD).
Concussions, the most frequently diagnosed type of TBI, involve brain movement inside the skull due to a sudden force. Johns Hopkins Medicine explains that this can lead to bruising, bleeding, or swelling, affecting brain function and overall health.
Prevalence and Risks in Australia
TBI presents a significant health concern in Australia, affecting a large number of individuals. A considerable proportion of these cases involve younger individuals, with men making up a majority of those impacted. The primary causes include road accidents, physical altercations, falls, and instances of abuse.
Developments in TBI Treatment and Diagnosis
Advancements in Drug Therapies
Research into pharmaceutical interventions for TBI continues to evolve, with ASX-listed companies driving innovation. Argenica Therapeutics (ASX:AGN) is developing ARG-007, a drug originally designed for stroke treatment, which has demonstrated effectiveness in reducing brain injury markers in preclinical TBI studies.
Nyrada (ASX:NYR) is engaged in the development of NYR-BI03, a neuroprotective compound under evaluation at the Walter Reed Army Institute of Research. This initiative utilizes advanced imaging techniques to examine the drug’s effects on brain health following injury.
Innovative Medical Devices for TBI Care
Several ASX-listed companies are developing medical devices to enhance TBI assessment and rehabilitation. Compumedics (ASX:CMP) is expanding its expertise in brain monitoring technology through Magnetoencephalography (MEG), a device that provides insights into TBI-related brain activity. The company also offers the DWL TBI Device, a portable solution for assessing blood flow in the brain.
Control Bionics (ASX:CBL) is utilizing electromyography (EMG) technology to improve communication and mobility for individuals with TBI. The NeuroNode Trilogy system allows users to interact with their surroundings through muscle signals, while the recently introduced NeuroStrip enhances this capability with wearable sensor technology.
EMvision Medical Devices (ASX:EMV) has developed the "emu," a portable brain scanner that employs high-frequency radio waves and artificial intelligence to generate detailed brain images. This device is designed to assist in rapid diagnosis in emergency environments. With regulatory progress and ongoing clinical evaluations, the company is working towards broader adoption of this innovative technology.
